Electrochemical oxidation pathway of the anti-cancer agent dasatinib using disposable pencil graphite electrode and its adsorptive stripping voltammetric determination in biological samples
The developed AdsSWV method based on disposible and cheap PGE was applied successfuly to the real urine samples and the recovery results are given in the range of 97.94% to 100.82%.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:The present study describes the use of pencil graphite electrode (PGE) for the investigation of electro-oxidation mechanism and voltammetric stripping determination of dasatinib (DST) in Britton-Robinson buffer solution (BR).
📊
Key Findings & Data:Relating to cyclic voltammetric studies, an irreversible oxidation signal was obtained at about 1.0 V.
💡
Conclusion & Impact:The developed AdsSWV method based on disposible and cheap PGE was applied successfuly to the real urine samples and the recovery results are given in the range of 97.94% to 100.82%.
The present study describes the use of pencil graphite electrode (PGE) for the investigation of electro-oxidation mechanism and voltammetric stripping determination of dasatinib (DST) in Britton-Robinson buffer solution (BR). Relating to cyclic voltammetric studies, an irreversible oxidation signal was obtained at about 1.0 V. The oxidation electrode process is adsorption-controlled and pH-dependent. For quantitative determination of DST, square wave adsorptive stripping voltammetry (AdsSWV) was employed in BR of pH 3.0. The oxidation peak current varies linearly with the DST concentration in the range of 0.0092 – 1.0 µM. Dedection (LOD) and quantification (LOQ) values are founded as 0.0028 µM and 0.0092 µM, respectively. The developed AdsSWV method based on disposible and cheap PGE was applied successfuly to the real urine samples and the recovery results are given in the range of 97.94% to 100.82%.
BAYRAKTEPE, D. E., POLAT, K., YAZAN, Z. (2018). Electrochemical oxidation pathway of the anti-cancer agent dasatinib using disposable pencil graphite electrode and its adsorptive stripping voltammetric determination in biological samples. Journal of the Turkish Chemical Society Section A: Chemistry, Cilt: 5 - Sayı: 2, 381–392. https://ajindex.com/articles/781375
Das J, Chen P, Norris D, Padmanabha R, Lin J, Moquin RV and Pang S. 2-Aminothiazole as a novel kinase inhibitor template. Structure− activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl] amino)]-1, 3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. Journal of medicinal chemistry 2006; 49(23):6819-6832
Montero JC, Seoane S. Ocaña A and Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clinical cancer research, 2011; 17(17):5546-5552
Steinberg, M. Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—positive acute lymphoblastic leukemia. Clinical therapeutics 2007; 29(11):2289-2308
Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE and Xie D. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer research 2006; 66(11):5790-5797
Vandyke K, Fitter S and Zannettino ACW. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation. Blood cancer journal 2011; 1(2), e2
Lankheet NA, Hillebrand MJ, Rosing H, Schellens JH, Beijnen JH and Huitema AD. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Biomedical Chromatography 2013; 27(4):466-476
Kralj E, Trontelj J, Pajič T and Kristl A. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry. Journal of Chromatography B 2012; 903:150-156
De Francia S, D’Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M and Di Perri G. New HPLC–MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. Journal of Chromatography B 2009; 877(18), 1721-1726
Hsieh Y, Galviz G, Zhou Q and Duncan C. Hydrophilic interaction liquid chromatography/tandem mass spectrometry for the simultaneous determination of dasatinib, imatinib and nilotinib in mouse plasma. Rapid Communications in Mass Spectrometry 2009; 23(9); 1364-1370